


# MSA-2 formulation for in vivo dosing

 Samantha A. Perera

Updated date: Jan 11, 2021

 An abbreviated version of this protocol was published in Science in Aug 2020

An orally available non-nucleotide STING agonist with antitumor activity

DOI: 10.1126/science.aba6098

## Detailed protocol

MSA-2 was solubilized in PBS with mild pH adjustment to dose mice at 5 ml/kg for all routes of administration

**How to cite:** (Readers should cite both the Bio-protocol preprint and the original research article where this protocol was used)

1. Perera, S. (2021). MSA-2 formulation for in vivo dosing. Bio-protocol Preprint. [bio-protocol.org/prep740](https://bio-protocol.org/prep740).
2. Pan, B., Perera, S. A., Piesvaux, J. A., Presland, J. P., Schroeder, G. K., Cumming, J. N., Trotter, B. W., Altman, M. D., Buevich, A. V., Cash, B., Cemerski, S., Chang, W., Chen, Y., Dandliker, P. J., Feng, G., Haidle, A., Henderson, T., Jewell, J., Kariv, I., Knemeyer, I., Kopinja, J., Lacey, B. M., Laskey, J., Lesburg, C. A., Liang, R., Long, B. J., Lu, M., Ma, Y., Minnihan, E. C., O'Donnell, G., Otte, R., Price, L., Rakhilina, L., Sauvagnat, B., Sharma, S., Tyagarajan, S., Woo, H., Wyss, D. F., Xu, S., Bennett, D. J. and Addona, G. H. (2020). An orally available non-nucleotide STING agonist with antitumor activity . Science 369(6506). DOI: [10.1126/science.aba6098](https://doi.org/10.1126/science.aba6098)

**Copyright:** Content may be subjected to copyright.